A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

Randomised Controlled ◽

HF ISSUED+ WITHDRAWN 29/09/06 - THIS ISRCTN90671233 WAS DUPLICATE OF 31557558 - A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis

http://isrctn.org/> ◽

10.1186/isrctn90671233 ◽

2012 ◽

Author(s):

Mike Boggild

Keyword(s):

Multiple Sclerosis ◽

Randomised Controlled Trial ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Controlled Trial ◽

Sequential Treatment ◽

Relapsing Remitting ◽

Randomised Controlled ◽

Interferon beta versus glatiramer acetate for relapsing-remitting multiple sclerosis

10.1002/14651858.cd009333 ◽

2011 ◽

Author(s):

Loredana La Mantia ◽

Alberto Vaona ◽

Marco Rovaris ◽

Francesco Berardo ◽

Serena Frau ◽

...

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Early Clinical Predictors of Sustained Disease-Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Glatiramer Acetate and Interferon Beta (PD5.008)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.pd5.008 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. PD5.008-PD5.008

Author(s):

G. Rojas ◽

C. Vrech ◽

F. Leguizamon ◽

S. Lindembaum ◽

A. Carra

Keyword(s):

Multiple Sclerosis ◽

Disease Activity ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Clinical Predictors ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Free Status

PNP15: COST-UTILITY ANALYSIS OF THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH GLATIRAMER ACETATE OR INTERFERON BETA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)64043-0 ◽

2003 ◽

Vol 6 (3) ◽

pp. 277

Author(s):

C Rubio-Terrés ◽

F Medina ◽

I Aristegui ◽

G Izquierdo

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Relapsing Remitting ◽

Cost-Effectiveness of Glatiramer Acetate and Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis, Based on the Combirx Study

Value in Health ◽

10.1016/j.jval.2013.08.1827 ◽

2013 ◽

Vol 16 (7) ◽

pp. A623

Author(s):

J. Darba ◽

L. Kaskens ◽

R.osa R Sánchez-de la

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

The CombiRx Trial: A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Participants with Relapsing-Remitting Multiple Sclerosis - Clinical Outcomes (PL02.003)

Neurology ◽

10.1212/wnl.78.1_meetingabstracts.pl02.003 ◽

2012 ◽

Vol 78 (Meeting Abstracts 1) ◽

pp. PL02.003-PL02.003 ◽

Cited By ~ 4

Author(s):

F. Lublin ◽

S. Cofield ◽

G. Cutter ◽

R. Conwit ◽

P. Narayana ◽

...

Keyword(s):

Multiple Sclerosis ◽

Clinical Outcomes ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Randomized Study ◽

Double Blind ◽

Combined Use ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/wnl.43.4.662 ◽

1993 ◽

Vol 43 (4) ◽

pp. 662-662 ◽

Cited By ~ 830

Author(s):

D. W. Paty ◽

D.K.B. Li ◽

◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

The Lancet ◽

10.1016/s0140-6736(12)61769-3 ◽

2012 ◽

Vol 380 (9856) ◽

pp. 1819-1828 ◽

Cited By ~ 688

Author(s):

Jeffrey A Cohen ◽

Alasdair J Coles ◽

Douglas L Arnold ◽

Christian Confavreux ◽

Edward J Fox ◽

...

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Relapsing Remitting ◽

Randomised Controlled ◽

Relapsing Remitting Multiple Sclerosis ◽

First Line Treatment

Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study

Journal of Medical Economics ◽

10.3111/13696998.2014.890936 ◽

2014 ◽

Vol 17 (3) ◽

pp. 215-222 ◽

Cited By ~ 11

Author(s):

Josep Darbà ◽

Lisette Kaskens ◽

Rainel Sánchez-de la Rosa

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Relapsing Remitting ◽

Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial

Neurology ◽

10.1212/01.wnl.0000407006.93844.fb ◽

2011 ◽

Vol 77 (15) ◽

pp. 1431-1431

Author(s):

D. W. Paty ◽

D. K. B. Li ◽

Keyword(s):

Multiple Sclerosis ◽

Interferon Beta ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽